New liquid embolic agent could shrink dangerous brain malformations
Disease control
Recruiting now
This study tests a new liquid embolic agent to treat brain arteriovenous malformations (AVMs), which are tangles of abnormal blood vessels that can cause bleeding or stroke. About 116 adults aged 18 to 80 with certain types of AVMs will receive the treatment and be followed for o…
Phase: NA • Sponsor: MicroPort NeuroTech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC